Ribociclib improves progression-free survival in advanced breast cancer

[News]

The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer...

More... (http://www.medicalnewstoday.com/releases/313403.php)